Notice & News | SILLAJEN

Notice & News

Targeting, Attacking, and Eradicating Cancers®

Notice & News

게시판

Total 25. ˙ 1/3 Page

25 SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC 2024-07-02
24 SillaJen Announces First Patient Enrolled in Part 2 of Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's Libtayo® (cemiplimab-rwlc) 2019-06-10
23 SillaJen and Lee's Pharmaceutical Announce First Patient Enrolled in the PHOCUS Trial in China Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer 2018-09-04
22 SillaJen Announces First Patient Enrolled in Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron’s Cemiplimab 2018-06-20
21 SillaJen Poster Presentation at 2018 GU ASCO Symposium Highlights New Clinical Data in RCC, Intravenous Delivery of Pexa-Vec, Oncolytic Immunotherapy 2018-02-23
20 Cancer-Killing Virus Acts by Alerting Immune System 2018-02-13
19 SillaJen and ABL Europe Expand Strategic Manufacturing Collaboration for Oncolytic Virus Therapies 2018-01-22
18 SillaJen Announces Collaboration with the National Cancer Institute for Development of Combination Therapy with SillaJen's Pexa-Vec Oncolytic Immunotherapy 2017-08-17
17 SillaJen and Lee's Pharmaceutical Announce Approval by the China CFDA to Commence Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer 2017-07-25
16 SillaJen teams up with Regeneron to combat kidney cancer 2017-05-10